Physician profile
John U Napoli
NPI 1225004997
$7,523.42
in general payments reported to CMS, 2019-2025
20 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $755 · 2021: $955 · 2022: $944 · 2023: $1,380 · 2024: $1,563 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,469.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,579.29 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,039.30 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,001.82 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $646.41 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $552.13 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $419.95 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $404.10 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $398.86 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $382.61 | 2020-2023 | Austedo Xr, Austedo |
| Lundbeck LLC | $320.42 | 2021-2025 | Rexulti |
| Allergan, INC. | $204.53 | 2019-2020 | |
| Axsome Therapeutics, INC. | $173.54 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $113.73 | 2022-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $109.06 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $54.17 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.56 | 2021-2024 | Trintellix |
| Bausch Health US, LLC | $32.42 | 2021 | |
| Eisai INC. | $15.23 | 2021 | |
| Indivior INC. | $14.50 | 2019 | |
| Merck Sharp & Dohme LLC | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Napoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.